155 related articles for article (PubMed ID: 37795861)
1. Cost-effectiveness analysis of CYP2C19 genotype-guided antiplatelet therapy for patients with acute minor ischemic stroke and high-risk transient ischemic attack in China.
Zhang Z; Bao Y; Gu Y; Zhang M; Li X
Br J Clin Pharmacol; 2024 Feb; 90(2):483-492. PubMed ID: 37795861
[TBL] [Abstract][Full Text] [Related]
2. Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack.
Narasimhalu K; Chan J; Ang YK; De Silva DA; Tan KB
Int J Stroke; 2024 Feb; 19(2):209-216. PubMed ID: 37679898
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.
Cai Z; Cai D; Wang R; Wang H; Yu Z; Gao F; Liu Y; Kang Y; Wu Z
Sci Rep; 2021 Apr; 11(1):7383. PubMed ID: 33795788
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
Wang Y; Yan BP; Liew D; Lee VWY
Pharmacogenomics J; 2018 Jan; 18(1):113-120. PubMed ID: 28117433
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
Micieli A; Singh N; Jahn B; Siebert U; Menon BK; Demchuk AM
Int J Stroke; 2023 Apr; 18(4):416-425. PubMed ID: 35739635
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.
Narasimhalu K; Ang YK; Tan DSY; De Silva DA; Tan KB
Clin Drug Investig; 2020 Nov; 40(11):1063-1070. PubMed ID: 32959334
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.
AlMukdad S; Elewa H; Arafa S; Al-Badriyeh D
Int J Cardiol; 2021 May; 331():27-34. PubMed ID: 33535078
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of
Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J
Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor Aspirin vs Clopidogrel Aspirin in
Wang A; Meng X; Tian X; Zuo Y; Bath PM; Li H; Xie X; Jing J; Lin J; Wang Y; Zhao X; Liu L; Li Z; Jiang Y; Xu J; Wang F; Chen W; Cao M; Li J; Wang Y
Neurology; 2023 Jan; 100(5):e497-e504. PubMed ID: 36535779
[TBL] [Abstract][Full Text] [Related]
11. Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
Pan Y; Meng X; Jin A; Johnston SC; Li H; Bath PM; Xie X; Jing J; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Yang H; Cheng J; Wang Z; Wang Y
JAMA Neurol; 2022 Aug; 79(8):739-745. PubMed ID: 35727586
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.
Kim JH; Tan DS; Chan MYY
Pharmacogenomics J; 2021 Apr; 21(2):243-250. PubMed ID: 33462345
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by
Zhou M; Chen W; Pan Y; Lin Y; Meng X; Zhao X; Liu L; Lin J; Li H; Wang Y; Wang Y
Aging (Albany NY); 2020 Dec; 13(3):3994-4006. PubMed ID: 33411687
[TBL] [Abstract][Full Text] [Related]
16. One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in
Meng X; Wang A; Tian X; Johnston C; Li H; Bath PM; Xu Q; Zhang Y; Xie X; Jing J; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Wang Y
Neurology; 2024 Feb; 102(3):e207809. PubMed ID: 38181311
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Xie X; Johnston SC; Wang A; Xu Q; Bath PM; Pan Y; Li H; Lin J; Wang Y; Zhao X; Li Z; Jiang Y; Liu L; Xu A; Jing J; Meng X; Wang Y
JAMA Netw Open; 2023 Jun; 6(6):e2317037. PubMed ID: 37279000
[TBL] [Abstract][Full Text] [Related]
18. Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack With a Single Small Subcortical Infarction.
Liu H; Jing J; Wang A; Xu Q; Meng X; Li H; Li Z; Wang Y
Neurology; 2023 Apr; 100(16):e1643-e1654. PubMed ID: 36697242
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor versus Clopidogrel in
Wang Y; Meng X; Wang A; Xie X; Pan Y; Johnston SC; Li H; Bath PM; Dong Q; Xu A; Jing J; Lin J; Niu S; Wang Y; Zhao X; Li Z; Jiang Y; Li W; Liu L; Xu J; Chang L; Wang L; Zhuang X; Zhao J; Feng Y; Man H; Li G; Wang B;
N Engl J Med; 2021 Dec; 385(27):2520-2530. PubMed ID: 34708996
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
